ArticleAmerican journal of respiratory and critical care medicine2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.
2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
In one paragraph
Article in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 100 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
21.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Efficacy and Mechanism of Anti-CD20 Antibodies in Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension Based on Multi Omics Studies
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.
- Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Chest · 2025Trial
- Real‑world pharmacovigilance of rituximab‑associated adverse reactions in children and adolescents: Disproportionality signal detection and time‑to‑onset pattern characterization using the FAERS database.Human vaccines & immunotherapeutics · 2026Article
- Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment.Chinese medical journal · 2026Review
- Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.Nature medicine · 2026Article
- Case-Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026Review
- Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.Pharmaceutics · 2026Review
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects.Biomolecules · 2026Review
- Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.Canadian respiratory journal · 2026Review
- Research progress on the mechanisms of cGAS-STING signaling in immune cell infiltration associated with vascular remodeling.Journal of translational medicine · 2025Review
- Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target.International journal of molecular sciences · 2025Review
- Long-Term Prognostic and Hemodynamic Outcomes of Intensive Immunosuppressive Therapy in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.International journal of rheumatic diseases · 2025Article
- Neutrophil-Endothelium Interaction Mediated by S100A9 Promotes Pulmonary Vascular Remodeling During Pulmonary Hypertension.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Interstitial Macrophages Drive Pulmonary Arteriole Medial Fibrosis in PAH.Circulation research · 2025Article
- Gut Microbiome in Pulmonary Arterial Hypertension-An Emerging Frontier.Infectious disease reports · 2025Review
- Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape.Expert opinion on therapeutic targets · 2025Review
- Transcriptional signatures of endothelial cells shape immune responses in cardiopulmonary health and disease.JCI insight · 2025Review
- Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Vascular Remodeling: The Multicellular Mechanisms of Pulmonary Hypertension.International journal of molecular sciences · 2025Review
- Pulmonary Arterial Hypertension in a Patient With Metastatic Lung Cancer on Pembrolizumab: Whom to Blame?Journal of medical cases · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 11 institutions in 1 country.
Roham T ZamanianDivision of Pulmonary, Allergy, and Critical Care Medicine and.ORCID 0000-0002-0734-0994
David BadeschDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Lorinda ChungDivision of Pulmonary, Allergy, and Critical Care Medicine and.
Robyn T DomsicDivision of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Thomas MedsgerDivision of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ashley PinckneyRho Federal Systems Division, Durham, North Carolina.
Lynette Keyes-ElsteinRho Federal Systems Division, Durham, North Carolina.
Carla D'AvetaRho Federal Systems Division, Durham, North Carolina.
Meagan SpychalaRho Federal Systems Division, Durham, North Carolina.
R James WhiteDivision of Pulmonary and Critical Care Medicine, University of Rochester, Rochester, New York.ORCID 0000-0003-1399-5206
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Fernando TorresDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern, Dallas, Texas.
Andrew J SweattDivision of Pulmonary, Allergy, and Critical Care Medicine and.
Jerry A MolitorDivision of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, Minnesota.
Dinesh KhannaDivision of Rheumatology, University of Michigan, Ann Arbor, Michigan.
Holden MaeckerDivision of Pulmonary, Allergy, and Critical Care Medicine and.
Beverly WelchNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland; and.
Ellen GoldmuntzNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland; and.
Mark R NicollsDivision of Pulmonary, Allergy, and Critical Care Medicine and.ORCID 0000-0001-9473-7422
Pulmonary and Allergy Associates · USRho (United States) · USNational Institute of Allergy and Infectious Diseases · USUniversity of Pittsburgh · USJohns Hopkins University · USThe University of Texas Southwestern Medical Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of Rochester · USVA Palo Alto Health Care System · US
Funding
Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1MSupplement - Inflammatory Triggers in B Cell AutoimmunityU19AI056363 · NIAID · DUKE UNIVERSITY · PI ST. CLAIR, EUGENE WILLIAM · 2003 to 2017
$35.3MVRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1MAutoimmunity Center of Excellence Clinical Research ProgramUM1AI110498 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOFSY, DAVID · 2014 to 2019
$31.4MThe Cellular Response to Elafin in PAHP01HL108797 · NHLBI · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2011 to 2021
$19.7MMHC peptide tetramers in type 1 diabetesU19AI046374 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 1999 to 2007
$9.6MiPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Prototype DiseaseU01HL107393 · NHLBI · STANFORD UNIVERSITY · PI RABINOVITCH, MARLENE, SNYDER, MICHAEL P. · 2011 to 2015
$8.7MEndothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAHR01HL138473 · NHLBI · STANFORD UNIVERSITY · PI Mark Robert Nicolls, Marlene Rabinovitch · 2017 to 2026
$4.9MCritical Role for Microvasculature in Airway TransplantationR01HL095686 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI NICOLLS, MARK ROBERT · 2010 to 2022
$4.7MUltra-Fast Epigenomic Maps for Monitoring AutoimmunityU19AI110491 · NIAID · STANFORD UNIVERSITY · PI UTZ, PAUL JOSEPH · 2014 to 2018
$3.6MA Critical Role for Leukotriene B4 in LymphedemaR01HL141105 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI NICOLLS, MARK ROBERT · 2019 to 2022
$2.3MAn Autoimmune Basis for Pulmonary Hypertension.R01HL082662 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI NICOLLS, MARK ROBERT · 2006 to 2009
$1.8MNHLBI NIH HHS K23 HL151892NHLBI NIH HHS P01 HL014985NHLBI NIH HHS P01 HL108797NHLBI NIH HHS R01 HL082662NHLBI NIH HHS R01 HL095686NHLBI NIH HHS R01 HL138473NHLBI NIH HHS R01 HL141105NHLBI NIH HHS U01 HL107393NIAID NIH HHS U19 AI046374NIAID NIH HHS U19 AI056363NIAID NIH HHS U19 AI110491NIAID NIH HHS UM1 AI110498NIAID NIH HHS UM2 AI117870
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedBiomarkers, PharmacologicalB-LymphocytesDouble-Blind MethodFemaleHumansImmunologic FactorsMaleMiddle AgedPulmonary Arterial HypertensionRituximabScleroderma, SystemicYoung AdultBiomarkers, PharmacologicalImmunologic FactorsRituximabpulmonary hypertensionsystemic sclerosistreatment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01086540ClinicalTrials.gov
NCT05828147ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.